Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
52
52 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- AZD0120GC012FPhase 39 trials
AstraZeneca · Newly Diagnosed Multiple Myeloma (NDMM), Relapsed AL Amyloidosis, Refractory AL Amyloidosis
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- CM336group, QiShen YiQi Dripping Pills 3 bagsPhase 37 trials
Keymed Biosciences Co.Ltd · Multiple Myeloma (MM), Primary Light-Chain Amyloidosis, Primary Immune Thrombocytopenia
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- CM313Phase 36 trials
Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- SCTC21CPhase 34 trials
Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)
- SG301Phase 33 trials
Hangzhou Sumgen Biotech Co., Ltd. · Systemic Lupus Erythematosus (SLE), Relapsed/Refractory Multiple Myeloma, Antibody Mediated Rejection
- Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
- bb2121BMS-986395Phase 32 trials
Bristol Myers Squibb · Multiple Myeloma
- BCD-248Phase 32 trials
Biocad · Relapsed/Refractory Multiple Myeloma, Myeloma Multiple
- BL-8040Phase 32 trials
BioLineRx, Ltd. · Multiple Myeloma, Pancreatic Adenocarcinoma
- CLR 131I-131-CLR1404, Iopofosine I 131 single dosePhase 32 trials
Cellectar Biosciences, Inc. · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia
- Equecabtagene AutoleucelFUCASOPhase 32 trials
Nanjing IASO Biotechnology Co., Ltd. · Refractory Immune-mediated Necrotizing Myopathy, Multiple Myeloma
- Purinostat MesylatePhase 32 trials
Chengdu Zenitar Biomedical Technology Co., Ltd · Relapsed or Refractory Multiple Myeloma (RRMM), Recurrent and Refractory Diffuse Large B-cell Lymphoma
- QLS32015Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Relapsed or Refractory Multiple Myeloma
- QLS4131Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Malignant Plasma Cell Neoplasms, Relapsed or Refractory Multiple Myeloma
- TQB2934Phase 32 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Multiple Myeloma, Systemic Light Chain Amyloidosis
- HLX15Phase 31 trial
Shanghai Henlius Biotech · Newly Diagnosed Multiple Myeloma
- Relma-celCAR, CD19-targeted Chimeric Antigen Receptor T CellsPhase 23 trials
Shanghai Ming Ju Biotechnology Co., Ltd. · Non-Hodgkin Lymphoma, Large B-cell Lymphoma, Multiple Myeloma
- BMS-986158Phase 22 trials
Bristol Myers Squibb · Myelofibrosis, Multiple Myeloma
- FeladilimabGSK3359609Phase 22 trials
GSK · Multiple Myeloma
- IDP-121Phase 22 trials
IDP Discovery Pharma S.L. · Small Cell Lung Cancer ( SCLC ), Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- MBS314Phase 22 trials
Beijing Mabworks Biotech Co., Ltd. · Relapsed or Refractory Multiple Myeloma, Multiple Myeloma
- REGN5459Vonsetamig, BCMAxCD3Phase 22 trials
Regeneron · Chronic Kidney Disease (CKD), Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- ABBV-2001Phase 21 trial
AbbVie · Multiple Myeloma
- AZD0305Phase 21 trial
AstraZeneca · Multiple Myeloma
- AZD4045Phase 21 trial
AstraZeneca · Relapsed or Refractory Multiple Myeloma
- BT02Phase 21 trial
Biotroy Therapeutics · Relapsed or Refractory Hematologic Malignancies, Leukemia, Lymphoma
- CD38Phase 21 trial
Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma
- CT071Phase 21 trial
CARsgen Therapeutics Co., Ltd. · Multiple Myeloma, Primary Plasma Cell Leukemia
- CYT-0851Phase 21 trial
Cyteir Therapeutics, Inc. · Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma
- Eque-celFully Human BCMA Chimeric Antigen Receptor Autologous T CellPhase 21 trial
Nanjing IASO Biotechnology Co., Ltd. · Relapsed/Refractory Multiple Myeloma
- F182112Phase 21 trial
Shandong New Time Pharmaceutical Co., LTD · Relapsed or Refractory Multiple Myeloma
- GPC-100Phase 21 trial
GPCR Therapeutics, Inc. · Multiple Myeloma
- GSK3174998Phase 21 trial
GSK · Multiple Myeloma
- HDP-101Phase 21 trial
Heidelberg Pharma AG · Multiple Myeloma, Plasma Cell Disorder
- HuL001Phase 21 trial
HuniLife Biotechnology, Inc. · Multiple Myeloma Refractory
- IDP-023Phase 21 trial
Indapta Therapeutics, INC. · NHL, Multiple Myeloma, Blood Cancer
- LBL-034Phase 21 trial
Nanjing Leads Biolabs Co.,Ltd · Relapsed/Refractory Multiple Myeloma
- OriCAR-017Phase 21 trial
OriCell Therapeutics Co., Ltd. · Relapsed and/or Refractory Multiple Myeloma
- REGN17372Phase 21 trial
Regeneron · Relapsed Refractory Multiple Myeloma (RRMM)
- REGN7945Phase 21 trial
Regeneron · Relapsed/Refractory Multiple Myeloma
- SG2918Phase 21 trial
Hangzhou Sumgen Biotech Co., Ltd. · Relapsed/Refractory Multiple Myeloma
- STI-6129Phase 21 trial
Zhejiang ACEA Pharmaceutical Co. Ltd. · Relapsed or Refractory Multiple Myeloma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.